MA46038B1 - Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale - Google Patents
Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection viraleInfo
- Publication number
- MA46038B1 MA46038B1 MA46038A MA46038A MA46038B1 MA 46038 B1 MA46038 B1 MA 46038B1 MA 46038 A MA46038 A MA 46038A MA 46038 A MA46038 A MA 46038A MA 46038 B1 MA46038 B1 MA 46038B1
- Authority
- MA
- Morocco
- Prior art keywords
- prophylaxis
- treatment
- viral infection
- compounds substituted
- sulfonimidoylpurinone
- Prior art date
Links
- 150000001875 compounds Chemical group 0.000 title abstract 4
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des composés de formule (i), dans laquelle r1, r2 et r3 sont tels que décrits ici, et leurs promédicaments ou leur sel, énantiomère ou diastéréoisomère pharmaceutiquement acceptables de ceux-ci, des compositions comprenant les composés et des procédés d'utilisation des composés comme agonistes de tlr7 pour le traitement et la prophylaxie d'infections virales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016097140 | 2016-08-29 | ||
| CN2017092653 | 2017-07-12 | ||
| PCT/EP2017/071514 WO2018041763A1 (fr) | 2016-08-29 | 2017-08-28 | Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA46038A MA46038A (fr) | 2019-07-03 |
| MA46038B1 true MA46038B1 (fr) | 2021-05-31 |
Family
ID=59738346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46038A MA46038B1 (fr) | 2016-08-29 | 2017-08-28 | Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10233184B2 (fr) |
| EP (2) | EP3865482A1 (fr) |
| JP (2) | JP7013467B2 (fr) |
| KR (2) | KR102459155B1 (fr) |
| CN (1) | CN109641904B (fr) |
| AU (3) | AU2017320742B2 (fr) |
| CA (1) | CA3034148A1 (fr) |
| CL (1) | CL2019000512A1 (fr) |
| CO (1) | CO2019000932A2 (fr) |
| CR (1) | CR20190087A (fr) |
| DK (1) | DK3504210T3 (fr) |
| ES (1) | ES2867849T3 (fr) |
| HR (1) | HRP20210621T1 (fr) |
| HU (1) | HUE053944T2 (fr) |
| IL (3) | IL293475B2 (fr) |
| MA (1) | MA46038B1 (fr) |
| MX (2) | MX383500B (fr) |
| MY (1) | MY197408A (fr) |
| PE (1) | PE20190476A1 (fr) |
| PH (1) | PH12019500432B1 (fr) |
| PL (1) | PL3504210T3 (fr) |
| PT (1) | PT3504210T (fr) |
| RS (1) | RS61752B1 (fr) |
| RU (1) | RU2751349C2 (fr) |
| SG (2) | SG11201901633WA (fr) |
| SI (1) | SI3504210T1 (fr) |
| TW (1) | TWI671300B (fr) |
| UA (1) | UA124270C2 (fr) |
| WO (1) | WO2018041763A1 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA120450C2 (uk) * | 2015-05-08 | 2019-12-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки і похідні сульфонімідоїлпуринону для лікування і профілактики вірусної інфекції |
| KR102459155B1 (ko) * | 2016-08-29 | 2022-10-28 | 에프. 호프만-라 로슈 아게 | 바이러스 감염의 치료 및 예방을 위한 7-치환된 설폰이미도일푸린온 화합물 |
| BR112019004560A2 (pt) * | 2016-09-13 | 2019-07-02 | Hoffmann La Roche | tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv |
| EP3752505B1 (fr) | 2018-02-12 | 2023-01-11 | F. Hoffmann-La Roche AG | Nouveaux composés et dérivés de sulfone pour le traitement et la prophylaxie d'une infection virale |
| JP7089596B2 (ja) * | 2018-02-28 | 2022-06-22 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 肝がんの治療及び予防のための７位置換スルホンイミドイルプリノン化合物及び誘導体 |
| SG11202101980VA (en) | 2018-09-12 | 2021-03-30 | Silverback Therapeutics Inc | Methods and composition for the treatment of disease with immune stimulatory conjugates |
| JP7287708B2 (ja) | 2019-02-08 | 2023-06-06 | プロジェニア インコーポレイテッド | Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途 |
| CA3151322A1 (fr) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Polytherapie comprenant des conjugues immunostimulants |
| WO2021168274A1 (fr) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Conjugués d'anticorps de nectine-4 et leurs utilisations |
| AU2021231160A1 (en) | 2020-03-02 | 2022-09-22 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
| EP4194008A4 (fr) | 2020-08-04 | 2025-01-08 | Progeneer Inc. | Ensemble adjuvant à action cinétique |
| WO2022031021A1 (fr) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | Vaccin à arnm comprenant un adjuvant permettant un contrôle cinétique |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
| CN114787165B (zh) * | 2020-09-27 | 2023-02-28 | 上海维申医药有限公司 | 大环tlr7激动剂、其制备方法、药物组合物及其用途 |
| GB202306325D0 (en) | 2023-04-28 | 2023-06-14 | Iksuda Therapeutics Ltd | Antibody-drug conjugate compounds, and methods of use and treatment |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0141927B1 (fr) * | 1983-08-18 | 1991-10-30 | Beecham Group Plc | Dérivés de guanine antiviraux |
| CA2230808C (fr) | 1996-07-03 | 2006-08-15 | Japan Energy Corporation | Nouveaux derives de purine |
| AUPO912997A0 (en) | 1997-09-11 | 1997-10-02 | Commonwealth Scientific And Industrial Research Organisation | Antiviral agents |
| US6329381B1 (en) * | 1997-11-28 | 2001-12-11 | Sumitomo Pharmaceuticals Company, Limited | Heterocyclic compounds |
| JPH11180981A (ja) * | 1997-12-19 | 1999-07-06 | Sumitomo Pharmaceut Co Ltd | 複素環誘導体 |
| TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| JP4189048B2 (ja) * | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| AU2003276824B8 (en) | 2002-03-15 | 2009-01-22 | The Regents Of The University Of Michigan | Novel 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purines as antiviral agents |
| MXPA05003193A (es) * | 2002-09-27 | 2005-06-08 | Sumitomo Pharma | Compuesto de adenina novedoso y uso del mismo. |
| MX2007013780A (es) | 2005-05-04 | 2008-02-05 | Pfizer Ltd | Derivados 2 amido-6-amino-8-oxo purina como moduladores del receptor como tipo peaje (toll) para el tratamiento del cancer y las infecciones virales tal como la hepatitis c. |
| DE102006053049A1 (de) | 2006-11-10 | 2008-05-15 | Daimler Ag | Staufach mit einer Abdeckeinrichtung |
| TWI434849B (zh) * | 2007-06-29 | 2014-04-21 | Gilead Sciences Inc | 類鐸（Ｔｏｌｌ－ｌｉｋｅ）受體７之調節劑 |
| CN101239980B (zh) | 2008-02-18 | 2011-06-22 | 靳广毅 | 免疫受体调节剂偶联体前体和偶联体及其应用 |
| SG172060A1 (en) * | 2008-12-09 | 2011-07-28 | Gilead Sciences Inc | Modulators of toll-like receptors |
| CN102666541B (zh) * | 2009-10-22 | 2015-11-25 | 吉里德科学公司 | 用于治疗特别是病毒感染的嘌呤或脱氮嘌呤的衍生物 |
| WO2011079016A1 (fr) | 2009-12-22 | 2011-06-30 | Gilead Sciences, Inc. | Méthodes de traitement d'une infection par le vhb et le vhc |
| US8501724B1 (en) * | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| AU2015303558B2 (en) | 2014-08-15 | 2018-07-12 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyrrolopyrimidine compounds used as TLR7 agonist |
| UA120450C2 (uk) * | 2015-05-08 | 2019-12-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки і похідні сульфонімідоїлпуринону для лікування і профілактики вірусної інфекції |
| KR102459155B1 (ko) * | 2016-08-29 | 2022-10-28 | 에프. 호프만-라 로슈 아게 | 바이러스 감염의 치료 및 예방을 위한 7-치환된 설폰이미도일푸린온 화합물 |
-
2017
- 2017-08-28 KR KR1020197008982A patent/KR102459155B1/ko active Active
- 2017-08-28 MA MA46038A patent/MA46038B1/fr unknown
- 2017-08-28 JP JP2019532184A patent/JP7013467B2/ja active Active
- 2017-08-28 RS RS20210489A patent/RS61752B1/sr unknown
- 2017-08-28 MY MYPI2019001082A patent/MY197408A/en unknown
- 2017-08-28 KR KR1020227036198A patent/KR20220147702A/ko not_active Ceased
- 2017-08-28 IL IL293475A patent/IL293475B2/en unknown
- 2017-08-28 EP EP20207475.3A patent/EP3865482A1/fr not_active Withdrawn
- 2017-08-28 MX MX2019002129A patent/MX383500B/es unknown
- 2017-08-28 PT PT177585270T patent/PT3504210T/pt unknown
- 2017-08-28 HR HRP20210621TT patent/HRP20210621T1/hr unknown
- 2017-08-28 TW TW106129087A patent/TWI671300B/zh active
- 2017-08-28 PL PL17758527T patent/PL3504210T3/pl unknown
- 2017-08-28 SG SG11201901633WA patent/SG11201901633WA/en unknown
- 2017-08-28 CR CR20190087A patent/CR20190087A/es unknown
- 2017-08-28 PE PE2019000346A patent/PE20190476A1/es unknown
- 2017-08-28 CA CA3034148A patent/CA3034148A1/fr active Pending
- 2017-08-28 UA UAA201903059A patent/UA124270C2/uk unknown
- 2017-08-28 IL IL284255A patent/IL284255B/en unknown
- 2017-08-28 SG SG10202010520SA patent/SG10202010520SA/en unknown
- 2017-08-28 HU HUE17758527A patent/HUE053944T2/hu unknown
- 2017-08-28 RU RU2019107957A patent/RU2751349C2/ru active
- 2017-08-28 EP EP17758527.0A patent/EP3504210B1/fr active Active
- 2017-08-28 PH PH1/2019/500432A patent/PH12019500432B1/en unknown
- 2017-08-28 WO PCT/EP2017/071514 patent/WO2018041763A1/fr not_active Ceased
- 2017-08-28 CN CN201780052692.6A patent/CN109641904B/zh active Active
- 2017-08-28 AU AU2017320742A patent/AU2017320742B2/en active Active
- 2017-08-28 DK DK17758527.0T patent/DK3504210T3/da active
- 2017-08-28 SI SI201730728T patent/SI3504210T1/sl unknown
- 2017-08-28 ES ES17758527T patent/ES2867849T3/es active Active
- 2017-08-29 US US15/689,136 patent/US10233184B2/en active Active
-
2019
- 2019-01-29 US US16/260,744 patent/US10752630B2/en active Active
- 2019-01-30 CO CONC2019/0000932A patent/CO2019000932A2/es unknown
- 2019-02-07 IL IL264710A patent/IL264710B/en unknown
- 2019-02-21 MX MX2021006902A patent/MX2021006902A/es unknown
- 2019-02-26 CL CL2019000512A patent/CL2019000512A1/es unknown
-
2020
- 2020-08-24 US US17/001,572 patent/US20200385387A1/en not_active Abandoned
-
2021
- 2021-06-24 AU AU2021204303A patent/AU2021204303B2/en active Active
-
2022
- 2022-01-17 JP JP2022004832A patent/JP7214900B2/ja active Active
- 2022-06-30 AU AU2022204697A patent/AU2022204697A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46038A (fr) | Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale | |
| MA41134A (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| MA41338A (fr) | Composés de pyrazine pour le traitement de maladies infectieuses | |
| MA54653B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA42410B1 (fr) | Oxystérols et leurs méthodes d'utilisation | |
| MA37942B1 (fr) | Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b | |
| MA39721A (fr) | Nouvelles héteroaryldihydropyrimidines condensées en position 6 pour le traitement et la prophylaxie d'une infection à virus de l'hépatite b | |
| WO2019035863A8 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques | |
| MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| MA38315A1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
| MA37712A2 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| MA40523A (fr) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
| TN2015000547A1 (fr) | Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1 | |
| MA37891B1 (fr) | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble | |
| MX380516B (es) | Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| MA35601B1 (fr) | Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1 | |
| MA40250A (fr) | Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k | |
| MA38009B1 (fr) | Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| MA42972B1 (fr) | Nouveaux composés sulfonimidoylpurinone et dérivés pour le traitement et la prophylaxie d'infection virale | |
| MA38591A1 (fr) | Héteroaryldihydropyrimidines pontées en position 6 pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b | |
| FR3058640B1 (fr) | Composes pour leur utilisation dans le traitement de la grippe |